At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
SPG601 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome
In Brief
A Phase 2 clinical trial evaluating SPG601 and Placebo for Fragile X Syndrome. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesUnited States
CollaboratorsAvance Clinical Pty Ltd.
Timeline
Phase 2CompletedFinished
20252026
First PostedMay 2024
Enrollment StartJul 2024
Primary CompletionDec 2024
TodayJul 2026
First PostedMay 14, 2024
Enrollment StartJul 5, 2024
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.1 years ago
Interventions
SPG601drug
synthetic small molecule
Placebodrug
Placebo